Pediatric Diabetic Ketoacidosis Treatment & Management

  • Author: Grace M Young, MD; Chief Editor: Richard G Bachur, MD   more...
 
Updated: Dec 14, 2009
 

Prehospital Care

  • Provide oxygen and advanced airway management in patients with diabetic ketoacidosis (DKA), if needed.[4]
  • Monitor the patient.
  • Provide isotonic intravenous fluids (eg, isotonic sodium chloride solution or lactated Ringer solution).
  • Perform fingerstick glucose testing.
  • Consider empiric naloxone if altered mental status is present.
Next

Emergency Department Care

Multiple goals are noted for the acute treatment of diabetic ketoacidosis (DKA), including volume resuscitation, identification and treatment of the precipitant event, insulin therapy, hourly monitoring of serum markers of diabetic ketoacidosis, and prevention of complications from rapid decreases in serum osmolarity. Each aspect of diabetic ketoacidosis management must be closely monitored.

Alter fluid, glucose, and insulin administration in response to the dynamic and often volatile metabolic changes that occur during treatment. A flow sheet is invaluable to monitor and document the progression of diabetic ketoacidosis management and is shown in the image below.

Sample diabetic ketoacidosis flow sheet. Sample diabetic ketoacidosis flow sheet.
  • Concurrent with management of diabetic ketoacidosis are basics of emergency resuscitation (eg, management of urgent airway, breathing, and circulation).
  • In addition to these basics, patients with diabetic ketoacidosis should remain on a diet of nothing by mouth (NPO), receive supplemental oxygen and, if bacterial infection is suspected, empiric antibiotic therapy.
  • The goal of the first hour of treatment is volume resuscitation and confirmation of diabetic ketoacidosis by laboratory studies.
    • Fluids - Isotonic sodium chloride solution bolus, 20 mL/kg intravenously over an hour or less
    • Glucose - None, unless serum glucose level falls to 250-300 mg/dL during rehydration
  • The goals of the second and succeeding hours are slow correction of hyperglycemia (with glucose level falling at a rate < 100 mg/dL/h), metabolic acidosis, and ketosis, in addition to continued volume replenishment.
    • Goals: These goals must be met in a manner that prevents too rapid a decrease in serum osmolarity.
      • This usually requires several hours and meticulous attention to the patient's response to therapy.
      • Careful observation is warranted to ensure that the patient does not become hypoglycemic.
      • Hypoglycemia may occur abruptly as insulin resistance resolves.
      • To this end, maintain glucose levels above 150-250 mg/dL.
      • During this period, admit the patient to an inpatient setting.
    • Fluids
      • Give isotonic sodium chloride solution or 0.45 isotonic sodium chloride solution (0.45% NaCl) with supplemental potassium at twice maintenance rate.
      • Add potassium as KCl, potassium phosphate, or potassium acetate.
      • If serum potassium level is in the low life-threatening range, consider replenishing potassium orally (or by nasogastric tube) in a liquid (not tablet) formulation. This corrects hypokalemia much more rapidly than intravenous replenishment, the rate of which must be reduced because of cardiac considerations.
      • If serum potassium level is less than 3.5, add 40 mEq/L to intravenous fluids.
      • If serum potassium level is 3.5-5, add 30 mEq/L to intravenous fluids.
      • If serum potassium level is 5-5.5, add 20 mEq/L to intravenous fluids.
      • If serum potassium level is greater than 5.5, do not add additional potassium to intravenous fluids.
      • If serum potassium level is not immediately available, perform an ECG to search for electrocardiographic signs of hyperkalemia.
    • Insulin
      • Do not give insulin until severe hypokalemia is corrected.
      • Then give 0.1 U/kg intravenous bolus; follow with insulin 0.1 U/kg/h intravenously by constant infusion. Prime all intravenous tubing before the bolus because insulin binds to intravenous tubing.
      • As a result of the potential for hypoglycemia, forego the insulin bolus if the serum glucose level is less than 500 mg/dL or if the child is known to be hypersensitive to exogenous insulin.
      • To prepare the insulin drip, add units of regular insulin equal to the patient's kilogram weight to 100 mL saline. Saturate the intravenous tubing with 20 mL of the insulin solution, and set the infusion rate equal to 10 mL/h. This provides 0.1 U/kg/h.
      • Use regular human insulin, unless the patient uses bovine insulin.
    • Glucose
      • Add 5% dextrose (D5 or D10) to intravenous fluids, if the child remains in ketoacidosis and serum glucose level approaches 250-300 mg/dL.
      • Do not discontinue the insulin drip, as the child remains in ketoacidosis for some time and insulin is critical in eliminating ketoacidosis.
      • Maintain the serum glucose concentration at 150-250 mg/dL during insulin infusion.
      • Titrate the insulin and glucose infusions, noting that 1 unit of regular insulin metabolizes 3 g of glucose.
      • The final goal is to obtain a serum glucose concentration within the reference range (serum glucose level, 100-150 mg/dL), to obtain neutral blood pH (pH =7.4; serum bicarbonate = 15-18 mEq/dL), and to eliminate serum ketones. This phase includes the transition from parenteral to subcutaneous insulin and from a fasting state to oral fluids. It usually occurs in the inpatient setting (see Further Inpatient Care) under the direction of a pediatric endocrinologist.
    • Fluids
      • Give 0.45% sodium chloride solution with dextrose and potassium up to twice maintenance rate.
      • Consider oral fluids if nausea is absent.
    • Insulin: Set the intravenous infusion at 0.05-0.10 U/kg/h.
    • Glucose: Consider 5-10% dextrose in intravenous fluids to maintain serum glucose level at least 150 mg/dL.
Previous
Next

Consultations

  • A pediatric endocrinologist may be useful in complicated cases.
Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Grace M Young, MD  Associate Professor, Department of Pediatrics, University of Maryland Medical Center

Grace M Young, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Emergency Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

James Li, MD  Former Assistant Professor, Division of Emergency Medicine, Harvard Medical School; Board of Directors, Remote Medicine

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Wayne Wolfram, MD, MPH  Associate Professor, Department of Emergency Medicine, Mercy St Vincent Medical Center

Wayne Wolfram, MD, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Pediatrics, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Richard G Bachur, MD  Associate Professor of Pediatrics, Harvard Medical School; Associate Chief and Fellowship Director, Attending Physician, Division of Emergency Medicine, Children's Hospital of Boston

Richard G Bachur, MD is a member of the following medical societies: American Academy of Pediatrics, Society for Academic Emergency Medicine, and Society for Pediatric Research

Disclosure: Nothing to disclose.

References

  1. Kisiel M, Marsons L. Recognizing and responding to hyperglycaemic emergencies. Br J Nurs. Oct 8-21 2009;18(18):1094-8. [Medline].

  2. Wolfsdorf J, Glaser N, Sperling MA; American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care. May 2006;29(5):1150-9. [Medline].

  3. Bui H, To T, Stein R, Fung K, Daneman D. Is Diabetic Ketoacidosis at Disease Onset a Result of Missed Diagnosis?. J Pediatr. Dec 2 2009;[Medline].

  4. [Guideline] Kitabchi AE, Umpierrez GE, Murphy MB, et al. Hyperglycemic crises in diabetes. Diabetes Care. Jan 2004;27 Suppl 1:S94-102. [Medline].

  5. Ackerman A. Cerebral edema in pediatric diabetic ketoacidosis: Can six patients make a difference?. Crit Care Med. Aug 2006;34(8):2258-9. [Medline].

  6. Agus MS, Wolfsdorf JI. Diabetic ketoacidosis in children. Pediatr Clin North Am. Aug 2005;52(4):1147-63, ix. [Medline].

  7. Alawi KA, Morrison GC, Fraser DD, Al-Farsi S, Collier C, Kornecki A. Insulin infusion via an intraosseous needle in diabetic ketoacidosis. Anaesth Intensive Care. Jan 2008;36(1):110-2. [Medline].

  8. Bismuth E, Laffel L. Can we prevent diabetic ketoacidosis in children?. Pediatr Diabetes. Oct 2007;8 Suppl 6:24-33. [Medline].

  9. Cardella F. Insulin therapy during diabetic ketoacidosis in children. Acta Biomed Ateneo Parmense. 2005;76 Suppl 3:49-54. [Medline].

  10. Cody D. Infant and toddler diabetes. Arch Dis Child. Aug 2007;92(8):716-9. [Medline].

  11. Dunger DB, Sperling MA, Acerini CL, et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child. Feb 2004;89(2):188-94. [Medline].

  12. Dunger DB, Sperling MA, Acerini CL, et al. European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement on diabetic ketoacidosis in children and adolescents. Pediatrics. Feb 2004;113(2):e133-40. [Medline].

  13. Edge JA, Hawkins MM, Winter DL, Dunger DB. The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. Arch Dis Child. Jul 2001;85(1):16-22. [Medline].

  14. Fiordalisi I, Novotny WE, Holbert D, Finberg L, Harris GD. An 18-yr prospective study of pediatric diabetic ketoacidosis: an approach to minimizing the risk of brain herniation during treatment. Pediatr Diabetes. Jun 2007;8(3):142-9. [Medline].

  15. Friedman AL. Choosing the right fluid and electrolytes prescription in diabetic ketoacidosis. J Pediatr. May 2007;150(5):455-6. [Medline].

  16. Glaser N. New perspectives on the pathogenesis of cerebral edema complicating diabetic ketoacidosis in children. Pediatr Endocrinol Rev. Jun 2006;3(4):379-86. [Medline].

  17. Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med. Jan 25 2001;344(4):264-9. [Medline].

  18. Glaser N, Kuppermann N. DKA-related cerebral edema and intravenous fluid therapy: potential pitfalls of uncontrolled retrospective studies. J Pediatr. Jan 2008;152(1):145; author reply 147-9. [Medline].

  19. Glaser N, Kuppermann N. The evaluation and management of children with diabetic ketoacidosis in the emergency department. Pediatr Emerg Care. Jul 2004;20(7):477-81; quiz 482-4. [Medline].

  20. Glaser NS, Wootton-Gorges SL, Buonocore MH, et al. Frequency of sub-clinical cerebral edema in children with diabetic ketoacidosis. Pediatr Diabetes. Apr 2006;7(2):75-80. [Medline].

  21. Green SM, Rothrock SG, Ho JD, et al. Failure of adjunctive bicarbonate to improve outcome in severe pediatric diabetic ketoacidosis. Ann Emerg Med. Jan 1998;31(1):41-8. [Medline].

  22. Hanas R, Lindgren F, Lindblad B. Diabetic ketoacidosis and cerebral oedema in Sweden--a 2-year paediatric population study. Diabet Med. Oct 2007;24(10):1080-5. [Medline].

  23. Hoorn EJ, Carlotti AP, Costa LA, MacMahon B, Bohn G, Zietse R, et al. Preventing a drop in effective plasma osmolality to minimize the likelihood of cerebral edema during treatment of children with diabetic ketoacidosis. J Pediatr. May 2007;150(5):467-73. [Medline].

  24. Lawson M. Predictors of acute complications in children with type I diabetes. J Pediatr. Nov 2002;141(5):739-40. [Medline].

  25. Mahmud FH, Ramsay DA, Levin SD, Singh RN, Kotylak T, Fraser DD. Coma with diffuse white matter hemorrhages in juvenile diabetic ketoacidosis. Pediatrics. Dec 2007;120(6):e1540-6. [Medline].

  26. Marcin JP, Glaser N, Barnett P, et al. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. J Pediatr. Dec 2002;141(6):793-7. [Medline].

  27. Munk MD. Pediatric DKA. The presentation, assessment & prehospital management of diabetic ketoacidosis in children. JEMS. Jun 2006;31(6):70-72, 74-80, 82; quiz 84. [Medline].

  28. Noyes KJ, Crofton P, Bath LE, Holmes A, Stark L, Oxley CD, et al. Hydroxybutyrate near-patient testing to evaluate a new end-point for intravenous insulin therapy in the treatment of diabetic ketoacidosis in children. Pediatr Diabetes. Jun 2007;8(3):150-6. [Medline].

  29. Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute complications in children with type 1 diabetes. JAMA. May 15 2002;287(19):2511-8. [Medline].

  30. Rosenbloom AL. Treatment of diabetic ketoacidosis and the risk of cerebral edema. J Pediatr. Jan 2008;152(1):146-7; author reply 147-9. [Medline].

  31. Sema A, Puliyel JM. Cerebral edema in diabetic ketoacidosis with serum sodium < 135 mEq/L. J Pediatr. Jan 2008;152(1):145-6; author reply 147-9. [Medline].

  32. Shastry RM, Bhatia V. Cerebral edema in diabetic ketoacidosis. Indian Pediatr. Aug 2006;43(8):701-8. [Medline].

  33. Takaya J, Ohashi R, Harada Y, Yamato F, Higashino H, Kobayashi Y, et al. Cerebral edema in a child with diabetic ketoacidosis before initial treatment. Pediatr Int. Jun 2007;49(3):395-6. [Medline].

  34. Wolfsdorf J, Craig ME, Daneman D, Dunger D, Edge J, Lee WR, et al. Diabetic ketoacidosis. Pediatr Diabetes. Feb 2007;8(1):28-43. [Medline].

 
Previous
Next
 
Sample diabetic ketoacidosis flow sheet.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.